BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15101732)

  • 1. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
    Bujassoum S; Rifkind J; Lipton JH
    Leuk Lymphoma; 2004 Feb; 45(2):401-3. PubMed ID: 15101732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
    Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
    Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
    Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate.
    Thavaraj V; Seth R
    World J Pediatr; 2008 May; 4(2):145-7. PubMed ID: 18661773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
    Xu Y; Wahner AE; Nguyen PL
    Arch Pathol Lab Med; 2004 Sep; 128(9):980-5. PubMed ID: 15338554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).
    Leis JF; Stepan DE; Curtin PT; Ford JM; Peng B; Schubach S; Druker BJ; Maziarz RT
    Leuk Lymphoma; 2004 Apr; 45(4):695-8. PubMed ID: 15160941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.
    Altintas A; Cil T; Kilinc I; Kaplan MA; Ayyildiz O
    J Neurooncol; 2007 Aug; 84(1):103-5. PubMed ID: 17318411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Lu DP
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):612-5. PubMed ID: 16378113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
    Aichberger KJ; Herndlhofer S; Agis H; Sperr WR; Esterbauer H; Rabitsch W; Knöbl P; Haas OA; Thalhammer R; Schwarzinger I; Sillaber C; Jäger U; Valent P
    Eur J Clin Invest; 2007 Oct; 37(10):808-13. PubMed ID: 17727673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
    Campbell LJ; Patsouris C; Rayeroux KC; Somana K; Januszewicz EH; Szer J
    Cancer Genet Cytogenet; 2002 Nov; 139(1):30-3. PubMed ID: 12547154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated central nervous system blast crisis in chronic myeloid leukemia.
    Rajappa S; Uppin SG; Raghunadharao D; Rao IS; Surath A
    Hematol Oncol; 2004 Dec; 22(4):179-81. PubMed ID: 15995975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
    Rytting ME; Wierda WG
    Leuk Lymphoma; 2004 Aug; 45(8):1623-6. PubMed ID: 15370215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low concentrations of STI571 in the cerebrospinal fluid: a case report.
    Petzer AL; Gunsilius E; Hayes M; Stockhammer G; Duba HC; Schneller F; Grünewald K; Poewe W; Gastl G
    Br J Haematol; 2002 Jun; 117(3):623-5. PubMed ID: 12028032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid.
    Takayama N; Sato N; O'Brien SG; Ikeda Y; Okamoto S
    Br J Haematol; 2002 Oct; 119(1):106-8. PubMed ID: 12358909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
    Hernández-Boluda JC; Cervantes F
    Drugs Today (Barc); 2002 Sep; 38(9):601-13. PubMed ID: 12582448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
    Aleem A; Siddiqui N
    Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.